<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02459509</url>
  </required_header>
  <id_info>
    <org_study_id>UW 15-105</org_study_id>
    <nct_id>NCT02459509</nct_id>
  </id_info>
  <brief_title>A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children</brief_title>
  <official_title>A Comparison of Two Doses of Intranasal Dexmedetomidine for Premedication in Children - a Double- Blind Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine if 4mcg/kg of intranasal dexmedetomidine is better
      than 2mcg/kg in successfully sedating a child prior to induction of anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dexmedetomidine is a selective alpha-2 adrenoreceptor agonist that has sedative, anxiolytic
      and analgesic properties without causing respiratory depression. It has been administered
      safely and effectively via a number of routes including as an intravenous infusion,
      intramuscularly, intranasally, buccally and orally .

      Yuen et al established that the median time of onset of sedation is 25-30 minutes, making it
      an ideal agent for preoperative sedation. The same group also studied doses of 1 mcg/kg and 2
      mcg/kg as a sedative premedication and found that the success rates of appropriate sedation
      at induction in children aged 1 to 8 years were 53% and 66% respectively, with a dose related
      increase in successful sedation.

      Much higher doses of dexmedetomidine have also been used safely. Administered intravenously,
      3mcg/kg of dexmedetomidine has been shown to provide satisfactory sedation for paediatric MRI
      in 97% of cases, without adverse effects.

      The investigators aim to show that high dose intranasal dexmedetomidine is a safe, effective
      and an easily administered sedative premedication.

      The investigators hypothesise that 4mcg/kg compared to 2mcg/kg of intranasal dexmedetomidine
      will lead to at least a 20% increase in the proportion of satisfactorily sedated patients at
      the time of anaesthesia induction.

      The primary outcome will be the proportion of children with satisfactory sedation at the time
      of anaesthesia induction.

      Suitable patients will be identified from the theatre lists and consent will be sought from
      their legal guardians during preassessment clinic or during their anaesthetic preoperative
      assessment on the ward.

      In a previous study, 66% of children aged 1-5 years were satisfactorily sedated at the time
      of induction with 2 mcg/kg of intranasal dexmedetomidine. In order to find a 20% difference
      with 4 mcg/kg of dexmedetomidine, the investigators' sample size needs to be 140 (70 in each
      group), for a power of 0.8 and a 5% false positive rate.

      The demographic data will be analysed by t test and chi-square test. The proportions of
      satisfactory sedation will be analysed by chi-square test. The onset sedation time and
      duration of sedation will be analysed by survival analysis. The vital signs over times will
      be expressed by percentage changes from baseline and estimated by mean and standard errors. A
      p-value&lt;0.05 will be considered statistically significant.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Satisfactory sedation</measure>
    <time_frame>From 30 minutes post drug administration to induction of anaesthesia (average 30 minutes)</time_frame>
    <description>The primary outcome will be the proportion of children with satisfactory sedation at the time of anaesthesic induction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to satisfactory sedation</measure>
    <time_frame>From time of drug administration to when Observer's Assessment of Alertness/ Sedation Score is 2 or less (from 0 minutes to 30 minutes)</time_frame>
    <description>Time taken from drug administration to when the child's sedation level is that of only responding after mild prodding or shaking</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>From drug administration to end of anaesthesia (on average 1 to 3 hours)</time_frame>
    <description>Blood pressure will be taken every 5 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>From drug administration to end of anaesthesia (on average 1 to 3 hours)</time_frame>
    <description>Heart rate will be taken every 5 minutes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturations</measure>
    <time_frame>From drug administration to end of anaesthesia (on average 1 to 3 hours)</time_frame>
    <description>Oxygen saturations will be taken every 5 minutes</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Anxiety, Separation</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine 2 mcg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dexmedetomidine 4 mcg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4 mcg/kg dexmedetomidine given intranasally once at least 30 minutes before anaesthetic induction</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>Either 2mcg/kg or 4mcg/kg of intranasal dexmedetomidine will be given to assess efficacy of preoperative sedation</description>
    <arm_group_label>Dexmedetomidine 2 mcg/kg</arm_group_label>
    <arm_group_label>Dexmedetomidine 4 mcg/kg</arm_group_label>
    <other_name>Precedex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All children of American Society of Anesthesiologists (ASA) physical status
             classification I or II (healthy) between the ages of 6 months and 5 years undergoing
             surgery at Queen Mary Hospital

        Exclusion Criteria:

          -  Any patient receiving other sedative premedication, allergy to dexmedetomidine, organ
             dysfunction, cardiac arrhythmia and congenital heart disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophie E Liu, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hong Kong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sophie E Liu, MBBS</last_name>
    <phone>852 55086630</phone>
    <email>sophieliu@doctors.org.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Theresa Hui, MBBS</last_name>
    <phone>852 95368149</phone>
    <email>huiwct@ha.org.hk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie E Liu, MBBS</last_name>
      <phone>55086630</phone>
      <email>sophieliu@doctors.org.uk</email>
    </contact>
    <contact_backup>
      <last_name>Theresa Hui, MBBS</last_name>
      <phone>95368149</phone>
      <email>huiwct@ha.org.hk</email>
    </contact_backup>
    <investigator>
      <last_name>Sophie E Liu, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Theresa Hui, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Grace Wong, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vivian Yuen, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael G Irwin, MBChB</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Silky Wong, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <results_reference>
    <citation>Pestieau SR, Quezado ZM, Johnson YJ, Anderson JL, Cheng YI, McCarter RJ, Choi S, Finkel JC. High-dose dexmedetomidine increases the opioid-free interval and decreases opioid requirement after tonsillectomy in children. Can J Anaesth. 2011 Jun;58(6):540-50. doi: 10.1007/s12630-011-9493-7. Epub 2011 Apr 2.</citation>
    <PMID>21461792</PMID>
  </results_reference>
  <results_reference>
    <citation>Mason KP, Zurakowski D, Zgleszewski SE, Robson CD, Carrier M, Hickey PR, Dinardo JA. High dose dexmedetomidine as the sole sedative for pediatric MRI. Paediatr Anaesth. 2008 May;18(5):403-11. doi: 10.1111/j.1460-9592.2008.02468.x. Epub 2008 Mar 18.</citation>
    <PMID>18363626</PMID>
  </results_reference>
  <results_reference>
    <citation>Mason KP, Lubisch NB, Robinson F, Roskos R. Intramuscular dexmedetomidine sedation for pediatric MRI and CT. AJR Am J Roentgenol. 2011 Sep;197(3):720-5. doi: 10.2214/AJR.10.6134.</citation>
    <PMID>21862817</PMID>
  </results_reference>
  <results_reference>
    <citation>Yuen VM, Irwin MG, Hui TW, Yuen MK, Lee LH. A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine. Anesth Analg. 2007 Aug;105(2):374-80.</citation>
    <PMID>17646493</PMID>
  </results_reference>
  <results_reference>
    <citation>Yuen VM, Hui TW, Irwin MG, Yao TJ, Chan L, Wong GL, Shahnaz Hasan M, Shariffuddin II. A randomised comparison of two intranasal dexmedetomidine doses for premedication in children. Anaesthesia. 2012 Nov;67(11):1210-6. doi: 10.1111/j.1365-2044.2012.07309.x. Epub 2012 Sep 5.</citation>
    <PMID>22950484</PMID>
  </results_reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2015</study_first_submitted>
  <study_first_submitted_qc>May 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2015</study_first_posted>
  <last_update_submitted>April 15, 2016</last_update_submitted>
  <last_update_submitted_qc>April 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sedation</keyword>
  <keyword>dexmedetomidine</keyword>
  <keyword>pediatric</keyword>
  <keyword>preoperative period</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety, Separation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

